First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group

✍ Scribed by R Paridaens; P Therasse; L Dirix; L Beex; M.J Piccart; D Cameron; T Cufer; K Roozendael; M Nooy; M.R Mattiacci

• Book ID: 118622192
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 172 KB
• Volume: 2
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(04)90844-0